WuXi Biologics remains in Hang Seng ESG 50 Index

WuXi Biologics retained inclusion in the Hang Seng ESG 50 Index, extending capital-market recognition of its ESG performance. Also remained in the Hang Seng Corporate Sustainability Benchmark Index, reinforcing its sustainability positioning with investors. HKQAA awarded an A+ rating in its 2026 sustainability assessment, which covered about 600 Hong Kong-listed constituents. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics (Cayman) Inc. published the original content used to generate this news brief via (Ref. ID: CN72056) on October 14, 2026, and is solely responsible for the information contained therein. (C)